Please assess the completion status of the following clinical trial:

Trial Title: Nebivolol in the Supine Hypertension of Autonomic Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female and aged 18 years or over.~* Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic Failure (Parkinson Disease, Multiple System Atrophy and Pure Autonomic Failure).~* A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic blood pressure of at least 10 mmHg, within 3 minutes after standing.~* Supine hypertension, defined as a systolic blood pressure \>150 mm Hg or diastolic blood pressure \> 90 mm Hg.~* Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.~Exclusion Criteria:~* Have changed dose, frequency and or type of prescribed medication, within two weeks of study start.~* Women of childbearing potential who are not using a medically accepted contraception.~* Have, in the investigator's opinion, any significant cardiac, systemic, hepatic, or renal illness.~* Diabetes mellitus or insipidus.~* In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing.~* In the investigator's opinion, are unable to adequately co-operate because of individual or family situation.~* In the investigator's opinion, are suffering from a mental disorder that interferes with the diagnosis and/or with the conduct of the study, e.g. schizophrenia, major depression, dementia.~* Are not able or willing to comply with the study requirements for the duration of the study.~* Persons on drugs with beta-blocking potential (e.g., amiodarone), persons taking scheduled or as needed nitrates and persons on drugs with alpha-blocking potential (e.g. tamsulosin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo capsule (Type: PLACEBO_COMPARATOR): Placebo capsule
- Nebivolol 5 mg (Type: EXPERIMENTAL): Nebivolol 5 mg capsule
- Metoprolol tartrate 50 mg (Type: ACTIVE_COMPARATOR): Metoprolol tartrate 50 mg single oral dose
- Sildenafil 25 mg (Type: ACTIVE_COMPARATOR): Sildenafil 25 mg single oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).